araag2/HINT huggingface dataset:
Clinical trial NCT00264875 (phase 3, status: completed)
Conditions: peripheral neuropathy, hiv infections
ICD codes: G90.09, Z21
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Participation in the preceding A0081066 double-blind trial met the entry criteria for
             that trial and completed A0081066 study through visit 7

        Exclusion Criteria:

          -  Experienced serious adverse event during the A0081066 trial that was considered
             related or possibly related to study medication by the investigator or sponsor

          -  non-compliant during A0081066 trial

          -  clinically significant or unstable medical condition both HIV-related and non-HIV
             related including but not limited to, cardiac, pulmonary or hepatorenal disease that,
             in the opinion of the investigator, would compromise participation in the study
Clinical trial NCT00113568 (phase 3, status: completed)
Conditions: menorrhagia, heavy menstrual bleeding
ICD codes: G43.831, G43.839, G43.821, G43.829, N94.9, N94.89
Drugs: tranexamic acid tablets (xp12b)
SMILES: NC[C@H]1CC[C@@H](CC1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women with menorrhagia

          -  18-49 years of age

          -  Regularly occuring menstrual periods

        Exclusion Criteria:

          -  History or presence of clinically significant disease or abnormalities that might
             confound the study

          -  History of bilateral oophorectomy or hysterectomy
Clinical trial NCT00312494 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: placebo, ziprasidone, ziprasidone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode
             manic (296.4x), or mixed (296.6x) as defined in Diagnostic and Statistical Manual of
             Mental Disorders - Text Revision (DSM-IV TR) and determined by the Mini International
             Neuropsychiatric Interview (MINI).

          -  At screening and at baseline (within 12 hours prior to the first dose of double-blind
             medication) subjects must have a Young Mania Rating Scale score of 18 or higher.

          -  Subjects must be actively receiving lithium or divalproex for their bipolar disorder
             in order to be considered for this study.

        Exclusion Criteria:

          -  Subjects with a Diagnostic and Statistical Manual of Mental Disorders IV- Text
             Revision (DSM-IV TR) diagnosis of schizophrenia (295.XX), schizoaffective disorder
             (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or
             psychotic disorder not otherwise specified (NOS) (298.9).

          -  Subjects with other DSM-IV-TR Axis I or Axis II disorders (in addition to Bipolar I
             disorder) are ineligible if the comorbid condition is clinically unstable, requires
             treatment, or has been a primary focus of treatment within the 6-month period prior to
             screening.
Clinical trial NCT00003152 (phase 3, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide, prednisone, vincristine sulfate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Previously untreated follicular stage III or IV non-Hodgkin's
        lymphoma At least one measurable mass

        PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: WHO 0-2 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Alkaline phosphatase and bilirubin less
        than 2.5 times upper limit of normal (ULN) (unless clearly related to NHL) Renal:
        Creatinine and BUN less than 2.5 times ULN (unless clearly related to NHL) Cardiovascular:
        No severe cardiac disease (e.g. severe heart failure requiring treatment or cardiac
        ejection fraction less than 45%) Neurologic: No neurologic disease Pulmonary: No pulmonary
        disease Other: Not pregnant No prior malignancies except nonmelanoma skin cancer or
        carcinoma in situ of the cervix Not HIV positive No psychiatric or metabolic disease

        PRIOR CONCURRENT THERAPY: See Disease Characteristics No concurrent immunotherapeutic
        drugs, chemotherapy, or radiotherapy
Clinical trial NCT00288236 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: rimonabant (sr141716), placebo
SMILES: CC1=C(N(N=C1C(=O)NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients aged greater than or equal to 18 years.

          -  Diagnosis of type 2 diabetes as defined by WHO criteria.

          -  Type 2 diabetes treated with insulin for at least 3 months (insulin dose of at least
             30 U/day for at least 4 weeks).

          -  HbA1C greater than or equal to 7%.

          -  Having signed the informed consent form.

        Exclusion Criteria:

        General:

          -  Weight loss > 5 kg within 3 months prior to screening visit.

          -  Pregnancy or lactation.

          -  Absence of medically approved contraceptive methods for females of childbearing
             potential.

          -  Administration of other investigational drugs within 30 days prior to screening visit.

          -  Previous participation in a Rimonabant study.

          -  Presence or history of allergic reaction or intolerance to multiple drugs.

        Related to endocrine and metabolic disorders:

          -  Presence of any clinically significant endocrine disease according to the
             Investigator.Note: euthyroid patients on replacement therapy will be included if the
             dosage of thyroxine is stable for at least 3 months prior to screening visit.

          -  Fasting C-peptide < 1.0 ng/mL.

        Related to other disorders:

          -  Presence of any severe medical or psychological condition that in the opinion of the
             Investigator would compromise the patient's safety or successful participation in the
             study.

          -  Presence or history of cancer within the past 5 years with the exception of adequately
             treated localized basal cell skin cancer or in situ uterine cervical cancer.

        Related to laboratory findings:

          -  Positive test for hepatitis B surface antigen and/or hepatitis C antibody.

          -  Abnormal TSH level (TSH > ULN or < LLN).

          -  Positive urine pregnancy test.

        Related to previous or concomitant medications:

          -  Antidiabetic drugs other than insulin within 3 months prior to screening visit.

          -  Drugs affecting weight (e.g., sibutramine, orlistat, herbal preparations, etc).
Clinical trial NCT01772056 (phase 3, status: terminated)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: fluticasone, cream, placebo,
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Reason stopped: 
    patient recruitment is very slow, economic grant has ended and the number of patients is enough
    according to sample size (22 children/ arm).
  
Eligibility criteria:

        Inclusion Criteria:

          -  Children, aged 2 to 10 years, with mild or moderate acute flare of AD (SCORAD up to
             50) and no treatment for this episode of AD.

          -  written informed consent to patients' parents.

        Exclusion Criteria:

          -  >30% of affected body surface area AD.

          -  Head affected.

          -  Fluticasone o vehicle allergy.

          -  Patients with any medical condition for which topical corticosteroids were
             contraindicated

          -  Patients with other dermatological conditions that may have prevented accurate
             assessment of AD

          -  Patients with receiving any concomitant medications that might have affected the
             study's outcome.

          -  Other medical history that could interfere with the evaluation of study treatment.
Clinical trial NCT00003941 (phase 3, status: completed)
Conditions: mediastinal cancer, metastatic cancer, testicular germ cell tumor
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, E29.0, E29.1, E29.8, E29.9, E89.5, N50.811, N50.812
Drugs: cisplatin, etoposide, ifosfamide
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven germ cell cancer

               -  Nonseminoma OR

               -  Combined seminoma and nonseminoma

          -  Poor prognosis (nonseminoma):

               -  Testis/retroperitoneal primary AND

               -  One of the following poor tumor markers

                    -  AFP greater than 10,000 iu/L

                    -  HCG greater than 50,000 iu/L

                    -  LDH greater than 10 times upper limit of normal OR

               -  Nonpulmonary visceral metastases (i.e., liver, bone, or brain) OR

               -  Mediastinal primary

        PATIENT CHARACTERISTICS:

        Age:

          -  16 to 50

        Sex:

          -  Male

        Performance status:

          -  WHO 0-3

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)

          -  AST no greater than 2 times ULN

        Renal:

          -  Creatinine clearance at least 60 mL/min (unless due to obstructive uropathy
             correctable by nephrostomy)

        Other:

          -  No other malignancy except basal cell skin cancer

          -  No neuropathy

          -  No other serious illness or medical condition

          -  No psychological, familial, sociological, or geographical condition that would prevent
             compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Concurrent radiotherapy for brain metastases allowed

        Surgery:

          -  Concurrent surgery for brain metastases allowed
Clinical trial NCT01159249 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  patients with type 2 diabetes inadequately controlled with diet, exercise and
             metformin, thiazolidinedione, or α-GI, or glinides monotherapy

          -  Age in the 20 years or over inclusive

          -  HbA1c in the range of ≥ 6.5 to ≤ 10%

        Exclusion Criteria:

          -  Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary
             forms of diabetes

          -  Significant heart diseases

          -  Significant diabetic complications
Clinical trial NCT01902992 (phase 3, status: completed)
Conditions: allergic rhinoconjunctivitis
ICD codes: D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, H10.45
Drugs: depiquick birch (dpg103), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          1. Patients must experience significant allergic symptoms on visit 2

          2. Medical history of allergic rhinitis and/or rhinoconjunctivitis with clinically
             relevant sensitization to tree allergens

          3. Specific IgE against birch allergens (CAP RAST ≥ 2)

        Exclusion criteria:

          1. History of significant clinical manifestations of allergy as a result of sensitization
             against grass or weed pollen and perennial allergens

          2. FEV1 or PEF value ≤ 80 %

          3. Persistent asthma (GINA ≥ 2)

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00534599 (phase 3, status: completed)
Conditions: anxiety, anxiety disorders, anxiety neuroses, anxiety states
ICD codes: F41.1, F41.9, F40.8, F40.9, F41.3, F41.8, F43.22, F41.1, F41.9, F40.9, F43.22, F41.0, F93.0, F12.980
Drugs: placebo, quetiapine fumarate xr
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

        Provision of Informed Consent

          -  Documented diagnosis of Generalized Anxiety Disorder

          -  Female patients must not be pregnant and be willing to use a reliable method of birth
             control

          -  Be able to understand and comply with study requirements

        Exclusion Criteria:

        Other psychiatric disorders that could confound the study results, as judged by the study
        doctor

          -  Moderate to severe depression

          -  Other clinically relevant diseases, as judged by the study doctor

          -  Medication that you are taking, as judged by the study doctor
Clinical trial NCT00429403 (phase 3, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: goserelin
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O
Reason stopped: 
    study stopped due to low accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Female patients older than 15 years and younger than 46 years.

          2. Primary breast cancer (Stage I, II, or III).

          3. Pathologically confirmed invasive breast carcinoma.

          4. Negative hormone-receptor status. (Negative defined as ER- and PR- staining in less
             than 10% of tumor cells, or tumors with less than or equal to 3 fm/mg cytosol protein
             on ligand-binding or enzyme-linked immunoassay).

          5. Premenopausal, verified before chemotherapy is begun as satisfying both:

               -  Cyclic vaginal bleeding.

               -  Follicle-stimulating hormone (FSH) is less than or equal to 15 IU/L. If patients
                  are taking oral contraceptives, FSH must be measured 1-2 weeks after
                  discontinuation. If FSH is greater than 15 and the patient has regular menses,
                  gynecologic consultation will be required for a decision on premenopausal status.

          6. Candidates for neoadjuvant and/or adjuvant chemotherapy for primary breast cancer.

          7. Treatment with at least four (4) cycles of chemotherapy as planned.

          8. Zubrod performance score of 0 or 1.

          9. Must consent to preservation of their ovarian function and indicate their awareness of
             the investigational nature of this study, in keeping with institutional policy.

         10. Willingness to use barrier contraception if sexually active.

        Exclusion Criteria:

          1. Pregnancy. Women must have a negative serum pregnancy test before initiation of
             injection.

          2. Hypersensitivity to any GnRH analog.

          3. Previous receipt of systemic chemotherapy.

          4. To receive at least 4 cycles of neoadjuvant and/or adjuvant chemotherapy with CMF.

          5. Stage IV breast cancer.

          6. Prothrombin time (PT) and partial prothrombin time (PTT) with INR > 1.5

          7. Platelets < 50,000/mm^3
Clinical trial NCT00291187 (phase 3, status: completed)
Conditions: insomnia
ICD codes: F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83
Drugs: 20 mg vec-162, 50 mg vec-162, 100 mg vec-162, placebo
SMILES: [H][C@@]1(CN=C(O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1, [H][C@@]1(CN=C(O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1, [H][C@@]1(CN=C(O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy subjects with no medical, psychiatric or current sleep disorders.

          -  Subject must sign a written consent form.

        Exclusion Criteria:

          -  Recent history of night shift work or jet lag.

          -  Prior experience sleeping in a sleep lab environment.

          -  History of sleep disorders.
Clinical trial NCT00638690 (phase 3, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: placebo, abiraterone acetate, prednisone/prednisolone
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Metastatic Castration-Resistant Prostate Cancer Progression after one or two prior
             cytotoxic chemotherapies

          -  At least one chemotherapy must have contained docetaxel

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status <= 2

          -  Medical or surgical castration with testosterone < 50 ng/dL

          -  Adequate bone marrow, hepatic and renal function

          -  Potassium >= 3.5 mmol/L

          -  Able to swallow the study drug whole as a tablet

          -  Informed Consent

        Exclusion Criteria:

          -  More than two prior cytotoxic chemotherapy regimens

          -  Prior Ketoconazole for prostate cancer

          -  Prior abiraterone acetate or other CYP17 inhibitor or investigational agents targeting
             the androgen receptor for prostate cancer

          -  Uncontrolled hypertension

          -  Active or symptomatic viral hepatitis or chronic liver disease

          -  History of pituitary or adrenal dysfunction

          -  Clinically significant heart disease

          -  Other malignancy

          -  Known brain metastasis

          -  GI disorder affecting absorption

          -  Not willing to use contraception
Clinical trial NCT00418834 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: ezetimibe and atorvastatin, atorvastatin, placebo (unspecified)
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is age 65 or older

          -  Patient is willing to maintain cholesterol lowering diet

          -  Patient has hyperlipidemia with LDL level greater than 70 mg/dl or 100 mg/dl depending
             on their CHD risk category

        Exclusion Criteria:

          -  A condition which, in the opinion of the investigator, would pose a risk to the
             patient or interfere with participation in the study

          -  Patient is unlikely to be compliant in taking study medication

          -  Patient with chronic or unstable medical condition

          -  Patient is taking unstable doses of medication

          -  Patient drinks more than 2 alcoholic drinks per day

          -  Patient has elevations in certain laboratory values (CK, AST, ALT)
Clinical trial NCT00608985 (phase 3, status: completed)
Conditions: primary insomnia
ICD codes: F51.01
Drugs: almorexant, almorexant, placebo, zolpidem
SMILES: CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CNC(=O)[C@H](N1CCC2=CC(OC)=C(OC)C=C2[C@@H]1CCC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult subjects (18-64 years) with a diagnosis of primary insomnia.

        Exclusion Criteria:

          -  History of any sleep disorder, or any Diagnostic and Statistical Manual of Mental
             Disorders, 4th edition (DSM-IV) axis I disorder other than primary insomnia.

          -  Sleep apnea, or restless legs syndrome.

          -  Daytime napping of more than 1 hour per day.

          -  Important caffeine consumption, heavy tobacco use, alcohol or drug abuse within 2
             years prior to the screening visit.

          -  Unwillingness to refrain from drugs, over-the-counter or herbal medication having an
             effect on sleep or behavior.
Clinical trial NCT01780428 (phase 3, status: completed)
Conditions: pain, nausea, vomiting
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, R11.0, R11.11, R11.2, R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8
Drugs: cl-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg), placebo
SMILES: CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Determination of being likely or possibly nausea-prone.

          -  Male or non-pregnant and non-lactating female.

          -  Surgical extraction of at least 2 impacted third molar teeth

          -  A female of child-bearing potential is eligible to participate in this study if she
             has a negative urine pregnancy test and is using an acceptable method of birth
             control.

          -  Surgical extraction of at least 2 impacted third molar teeth.

          -  Presence of at least moderate post-operative pain.

        Exclusion Criteria:

          -  Medial Condition, presence of a serious medical condition.

          -  Active local infection.

          -  Drug Allergy history of hypersensitivity to an Opioid, Promethazine, Acetaminophen.

          -  Caffeine use since midnight before the operation.

          -  Use of an IND Drug within past 30 days.

          -  Previous participation in this study.

          -  Pregnant or lactating.

          -  Employee of the PI,sub-investigator or Charleston Labs or relative of an employee.
Clinical trial NCT00191919 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: duloxetine hydrochloride, placebo
SMILES: CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Major Depressive Disorder according to DSM-IV criteria with at least one previous
             depressive episode in the patient's medical history

          -  Painful physical symptoms as measured by the Brief Pain Inventory-Short Form

        Exclusion Criteria:

          -  Any anxiety disorder as a primary diagnosis within the past 6 months (including panic
             disorder, OCD, PTSD, generalized anxiety disorder and social phobia)

          -  Any diagnosis of bipolar disorder, schizophrenia, or other psychotic disorders